. Author manuscript; available in PMC: 2018 Dec 1.

Published in final edited form as: Ann Surg Oncol. 2017 Sep 15;24(13):3896–3902. doi: 10.1245/s10434-017-6085-y

Table 2.

Treatment characteristics of study cohort (n = 321)

		Total n = 321
Breast Surgery^¥
	Lumpectomy	47 (15%)
	Mastectomy	272 (85%)
Axillary Lymph Node Dissection		321 (100%)
Chemotherapy
	AC-T	274 (85%)
	CMF	1 (< 1%)
	TC	26 (8%)
	Taxane only	13 (4%)
	Other^*	7 (2%)
Anti-HER2 Therapy^§
	Trastuzumab	70 (64%)
	Trastuzumab/pertuzumab	32 (29%)
	Other^**	8 (7%)

AC-T, doxorubicin and cyclophosphamide with the addition of a taxane; CMF, cyclophosphamide, methotrexate, 5 fluorouracil; TC, taxane and cyclophosphamide

^¥

2 patients with occult primary breast cancer had no primary breast surgery

includes AC (n = 4), TC-vinorelbine (n = 1), cisplatin (n = 1), AT (n = 1)

^**

includes trastuzumab/lapatinib (n = 7), lapatinib (n = 1)

^§

calculated for 110 HER2 positive patients